{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T18:34:49Z","timestamp":1794422089682,"version":"4.9.1"},"reference-count":218,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1038\/s41571-023-00785-8","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T11:03:24Z","timestamp":1687777404000},"page":"583-603","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":142,"title":["Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5789-3354","authenticated-orcid":false,"given":"Andrew Maltez","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5589-9688","authenticated-orcid":false,"given":"Marine","family":"Fidelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1955-9149","authenticated-orcid":false,"given":"Bertrand","family":"Routy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9334-4405","authenticated-orcid":false,"given":"Guido","family":"Kroemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3438-7576","authenticated-orcid":false,"given":"Jennifer A.","family":"Wargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Segata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1596-0998","authenticated-orcid":false,"given":"Laurence","family":"Zitvogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"key":"785_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31\u201346 (2022).","journal-title":"Cancer Discov."},{"key":"785_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14187-x","volume":"11","author":"LD Cassidy","year":"2020","unstructured":"Cassidy, L. D. et al. Temporal inhibition of autophagy reveals segmental reversal of ageing with increased cancer risk. Nat. Commun. 11, 307 (2020).","journal-title":"Nat. Commun."},{"key":"785_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1158\/2159-8290.CD-16-0241","volume":"7","author":"M Demaria","year":"2017","unstructured":"Demaria, M. et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov. 7, 165\u2013176 (2017).","journal-title":"Cancer Discov."},{"key":"785_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cell.2020.11.034","volume":"184","author":"C L\u00f3pez-Ot\u00edn","year":"2021","unstructured":"L\u00f3pez-Ot\u00edn, C. & Kroemer, G. Hallmarks of health. Cell 184, 33\u201363 (2021).","journal-title":"Cell"},{"key":"785_CR5","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/s43018-020-00122-3","volume":"1","author":"L Derosa","year":"2020","unstructured":"Derosa, L. et al. The immuno-oncological challenge of COVID-19. Nat. Cancer 1, 946\u2013964 (2020).","journal-title":"Nat. Cancer"},{"key":"785_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2014.11.009","volume":"27","author":"MR Rutkowski","year":"2015","unstructured":"Rutkowski, M. R. et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell 27, 27\u201340 (2015).","journal-title":"Cancer Cell"},{"key":"785_CR7","doi-asserted-by":"publisher","first-page":"103012","DOI":"10.1016\/j.isci.2021.103012","volume":"24","author":"AM McKee","year":"2021","unstructured":"McKee, A. M. et al. Antibiotic-induced disturbances of the gut microbiota result in accelerated breast tumor growth. iScience 24, 103012 (2021).","journal-title":"iScience"},{"key":"785_CR8","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1158\/0008-5472.CAN-18-3464","volume":"79","author":"C Buchta Rosean","year":"2019","unstructured":"Buchta Rosean, C. et al. Preexisting commensal dysbiosis is a host-intrinsic regulator of tissue inflammation and tumor cell dissemination in hormone receptor-positive breast cancer. Cancer Res. 79, 3662\u20133675 (2019).","journal-title":"Cancer Res."},{"key":"785_CR9","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.50240","volume":"9","author":"TS Ghosh","year":"2020","unstructured":"Ghosh, T. S., Das, M., Jeffery, I. B. & O\u2019Toole, P. W. Adjusting for age improves identification of gut microbiome alterations in multiple diseases. eLife 9, e50240 (2020).","journal-title":"eLife"},{"key":"785_CR10","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s42255-021-00348-0","volume":"3","author":"T Wilmanski","year":"2021","unstructured":"Wilmanski, T. et al. Gut microbiome pattern reflects healthy ageing and predicts survival in humans. Nat. Metab. 3, 274\u2013286 (2021).","journal-title":"Nat. Metab."},{"key":"785_CR11","doi-asserted-by":"publisher","first-page":"18224","DOI":"10.18632\/oncotarget.24804","volume":"9","author":"LB Bindels","year":"2018","unstructured":"Bindels, L. B. et al. Increased gut permeability in cancer cachexia: mechanisms and clinical relevance. Oncotarget 9, 18224\u201318238 (2018).","journal-title":"Oncotarget"},{"key":"785_CR12","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1002\/jcsm.12804","volume":"12","author":"J Ubachs","year":"2021","unstructured":"Ubachs, J. et al. Gut microbiota and short-chain fatty acid alterations in cachectic cancer patients. J. Cachexia Sarcopenia Muscle 12, 2007\u20132021 (2021).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"785_CR13","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1126\/science.aar6918","volume":"359","author":"L Zitvogel","year":"2018","unstructured":"Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G. & Gajewski, T. F. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science 359, 1366\u20131370 (2018).","journal-title":"Science"},{"key":"785_CR14","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1073\/pnas.1000097107","volume":"108","author":"MJ Claesson","year":"2011","unstructured":"Claesson, M. J. et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc. Natl Acad. Sci. USA 108, 4586\u20134591 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"785_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05470-4","volume":"9","author":"HM Roager","year":"2018","unstructured":"Roager, H. M. & Licht, T. R. Microbial tryptophan catabolites in health and disease. Nat. Commun. 9, 3294 (2018).","journal-title":"Nat. Commun."},{"key":"785_CR16","doi-asserted-by":"publisher","first-page":"E7506","DOI":"10.1073\/pnas.1706464114","volume":"114","author":"R Sonowal","year":"2017","unstructured":"Sonowal, R. et al. Indoles from commensal bacteria extend healthspan. Proc. Natl Acad. Sci. USA 114, E7506\u2013E7515 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"785_CR17","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.ajpath.2018.01.011","volume":"188","author":"EE Alexeev","year":"2018","unstructured":"Alexeev, E. E. et al. Microbiota-derived indole metabolites promote human and murine intestinal homeostasis through regulation of interleukin-10 receptor. Am. J. Pathol. 188, 1183\u20131194 (2018).","journal-title":"Am. J. Pathol."},{"key":"785_CR18","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/ismej.2015.209","volume":"10","author":"LB Bindels","year":"2016","unstructured":"Bindels, L. B. et al. Synbiotic approach restores intestinal homeostasis and prolongs survival in leukaemic mice with cachexia. ISME J. 10, 1456\u20131470 (2016).","journal-title":"ISME J."},{"key":"785_CR19","doi-asserted-by":"publisher","first-page":"eaan5931","DOI":"10.1126\/science.aan5931","volume":"360","author":"C Ma","year":"2018","unstructured":"Ma, C. et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science 360, eaan5931 (2018).","journal-title":"Science"},{"key":"785_CR20","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41586-019-1865-0","volume":"577","author":"X Song","year":"2020","unstructured":"Song, X. et al. Microbial bile acid metabolites modulate gut ROR\u03b3+ regulatory T cell homeostasis. Nature 577, 410\u2013415 (2020).","journal-title":"Nature"},{"key":"785_CR21","doi-asserted-by":"publisher","first-page":"eabo2296","DOI":"10.1126\/science.abo2296","volume":"380","author":"M Fidelle","year":"2023","unstructured":"Fidelle, M. et al. A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers. Science 380, eabo2296 (2023).","journal-title":"Science"},{"key":"785_CR22","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41586-021-03832-5","volume":"599","author":"Y Sato","year":"2021","unstructured":"Sato, Y. et al. Novel bile acid biosynthetic pathways are enriched in the microbiome of centenarians. Nature 599, 458\u2013464 (2021).","journal-title":"Nature"},{"key":"785_CR23","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41586-022-04567-7","volume":"604","author":"R Gacesa","year":"2022","unstructured":"Gacesa, R. et al. Environmental factors shaping the gut microbiome in a Dutch population. Nature 604, 732\u2013739 (2022).","journal-title":"Nature"},{"key":"785_CR24","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gutjnl-2015-310861","volume":"65","author":"MA Jackson","year":"2016","unstructured":"Jackson, M. A. et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 65, 749\u2013756 (2016).","journal-title":"Gut"},{"key":"785_CR25","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1158\/2159-8290.CD-21-0999","volume":"12","author":"S Yonekura","year":"2022","unstructured":"Yonekura, S. et al. Cancer induces a stress ileopathy depending on \u03b2-adrenergic receptors and promoting dysbiosis that contributes to carcinogenesis. Cancer Discov. 12, 1128\u20131151 (2022).","journal-title":"Cancer Discov."},{"key":"785_CR26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.eururo.2020.04.044","volume":"78","author":"L Derosa","year":"2020","unstructured":"Derosa, L. et al. Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients. Eur. Urol. 78, 195\u2013206 (2020).","journal-title":"Eur. Urol."},{"key":"785_CR27","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1038\/s41418-021-00784-1","volume":"28","author":"S Terrisse","year":"2021","unstructured":"Terrisse, S. et al. Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. Cell Death Differ. 28, 2778\u20132796 (2021).","journal-title":"Cell Death Differ."},{"key":"785_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004191","volume":"10","author":"S Terrisse","year":"2022","unstructured":"Terrisse, S. et al. Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer. J. Immunother. Cancer 10, e004191 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"785_CR29","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1126\/science.abf8403","volume":"374","author":"N Pernigoni","year":"2021","unstructured":"Pernigoni, N. et al. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. Science 374, 216\u2013224 (2021).","journal-title":"Science"},{"key":"785_CR30","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1126\/science.aah5043","volume":"357","author":"LT Geller","year":"2017","unstructured":"Geller, L. T. et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357, 1156\u20131160 (2017).","journal-title":"Science"},{"key":"785_CR31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/ajcp\/44.1.36","volume":"44","author":"JR Collins","year":"1965","unstructured":"Collins, J. R. Small intestinal mucosal damage with villous atrophy: a review of the literature. Am. J. Clin. Pathol. 44, 36\u201344 (1965).","journal-title":"Am. J. Clin. Pathol."},{"key":"785_CR32","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000197269","volume":"7","author":"T Gilat","year":"1972","unstructured":"Gilat, T., Fischel, B., Danon, J. & Loewenthal, M. Morphology of small bowel mucosa in malignancy. Digestion 7, 147\u2013155 (1972).","journal-title":"Digestion"},{"key":"785_CR33","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/nm.4194","volume":"22","author":"D Stanley","year":"2016","unstructured":"Stanley, D. et al. Translocation and dissemination of commensal bacteria in post-stroke infection. Nat. Med. 22, 1277\u20131284 (2016).","journal-title":"Nat. Med."},{"key":"785_CR34","doi-asserted-by":"publisher","first-page":"7428","DOI":"10.1523\/JNEUROSCI.1114-16.2016","volume":"36","author":"V Singh","year":"2016","unstructured":"Singh, V. et al. Microbiota dysbiosis controls the neuroinflammatory response after stroke. J. Neurosci. 36, 7428\u20137440 (2016).","journal-title":"J. Neurosci."},{"key":"785_CR35","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1056\/NEJMra1600266","volume":"375","author":"SV Lynch","year":"2016","unstructured":"Lynch, S. V. & Pedersen, O. The human intestinal microbiome in health and disease. N. Engl. J. Med. 375, 2369\u20132379 (2016).","journal-title":"N. Engl. J. Med."},{"key":"785_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18476-8","volume":"11","author":"VK Gupta","year":"2020","unstructured":"Gupta, V. K. et al. A predictive index for health status using species-level gut microbiome profiling. Nat. Commun. 11, 4635 (2020).","journal-title":"Nat. Commun."},{"key":"785_CR37","doi-asserted-by":"publisher","unstructured":"Blanco-M\u00edguez, A. et al. Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-023-01688-w (2023)","DOI":"10.1038\/s41587-023-01688-w"},{"key":"785_CR38","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97\u2013103 (2018).","journal-title":"Science"},{"key":"785_CR39","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41591-022-01695-5","volume":"28","author":"KA Lee","year":"2022","unstructured":"Lee, K. A. et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat. Med. 28, 535\u2013544 (2022).","journal-title":"Nat. Med."},{"key":"785_CR40","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41591-022-01698-2","volume":"28","author":"JA McCulloch","year":"2022","unstructured":"McCulloch, J. A. et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat. Med. 28, 545\u2013556 (2022).","journal-title":"Nat. Med."},{"key":"785_CR41","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","volume":"28","author":"L Derosa","year":"2022","unstructured":"Derosa, L. et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat. Med. 28, 315\u2013324 (2022).","journal-title":"Nat. Med."},{"key":"785_CR42","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91\u201397 (2018).","journal-title":"Science"},{"key":"785_CR43","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/CMR.0000000000000656","volume":"30","author":"TT Wind","year":"2020","unstructured":"Wind, T. T. et al. Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma. Melanoma Res. 30, 235\u2013246 (2020).","journal-title":"Melanoma Res."},{"key":"785_CR44","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.neo.2017.08.004","volume":"19","author":"AE Frankel","year":"2017","unstructured":"Frankel, A. E. et al. Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia 19, 848\u2013855 (2017).","journal-title":"Neoplasia"},{"key":"785_CR45","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1053\/j.gastro.2022.03.054","volume":"163","author":"N Nagata","year":"2022","unstructured":"Nagata, N. et al. Metagenomic identification of microbial signatures predicting pancreatic cancer from a multinational study. Gastroenterology 163, 222\u2013238 (2022).","journal-title":"Gastroenterology"},{"key":"785_CR46","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1136\/gutjnl-2015-309800","volume":"66","author":"J Yu","year":"2017","unstructured":"Yu, J. et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut 66, 70\u201378 (2017).","journal-title":"Gut"},{"key":"785_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7528","volume":"6","author":"Q Feng","year":"2015","unstructured":"Feng, Q. et al. Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat. Commun. 6, 6528 (2015).","journal-title":"Nat. Commun."},{"key":"785_CR48","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41591-019-0458-7","volume":"25","author":"S Yachida","year":"2019","unstructured":"Yachida, S. et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat. Med. 25, 968\u2013976 (2019).","journal-title":"Nat. Med."},{"key":"785_CR49","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-019-0406-6","volume":"25","author":"J Wirbel","year":"2019","unstructured":"Wirbel, J. et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat. Med. 25, 679\u2013689 (2019).","journal-title":"Nat. Med."},{"key":"785_CR50","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41591-019-0405-7","volume":"25","author":"AM Thomas","year":"2019","unstructured":"Thomas, A. M. et al. Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. Nat. Med. 25, 667\u2013678 (2019).","journal-title":"Nat. Med."},{"key":"785_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155362","volume":"11","author":"E Vogtmann","year":"2016","unstructured":"Vogtmann, E. et al. Colorectal cancer and the human gut microbiome: reproducibility with whole-genome shotgun sequencing. PLoS ONE 11, e0155362 (2016).","journal-title":"PLoS ONE"},{"key":"785_CR52","doi-asserted-by":"publisher","first-page":"766","DOI":"10.15252\/msb.20145645","volume":"10","author":"G Zeller","year":"2014","unstructured":"Zeller, G. et al. Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol. Syst. Biol. 10, 766 (2014).","journal-title":"Mol. Syst. Biol."},{"key":"785_CR53","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1126\/science.aaz7015","volume":"374","author":"CN Spencer","year":"2021","unstructured":"Spencer, C. N. et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science 374, 1632\u20131640 (2021).","journal-title":"Science"},{"key":"785_CR54","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1136\/gutjnl-2021-324755","volume":"71","author":"E Kartal","year":"2022","unstructured":"Kartal, E. et al. A faecal microbiota signature with high specificity for pancreatic cancer. Gut 71, 1359\u20131372 (2022).","journal-title":"Gut"},{"key":"785_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0672-4","volume":"11","author":"BA Peters","year":"2019","unstructured":"Peters, B. A. et al. Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients. Genome Med. 11, 61 (2019).","journal-title":"Genome Med."},{"key":"785_CR56","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41591-020-01183-8","volume":"27","author":"F Asnicar","year":"2021","unstructured":"Asnicar, F. et al. Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals. Nat. Med. 27, 321\u2013332 (2021).","journal-title":"Nat. Med."},{"key":"785_CR57","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.chom.2019.01.004","volume":"25","author":"F De Filippis","year":"2019","unstructured":"De Filippis, F. et al. Distinct genetic and functional traits of human intestinal Prevotella copri strains are associated with different habitual diets. Cell Host Microbe 25, 444\u2013453.e3 (2019).","journal-title":"Cell Host Microbe"},{"key":"785_CR58","doi-asserted-by":"publisher","DOI":"10.1093\/gigascience\/giz004","volume":"8","author":"DB Dhakan","year":"2019","unstructured":"Dhakan, D. B. et al. The unique composition of Indian gut microbiome, gene catalogue, and associated fecal metabolome deciphered using multi-omics approaches. Gigascience 8, giz004 (2019).","journal-title":"Gigascience"},{"key":"785_CR59","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nature11234","volume":"486","author":"Human Microbiome Project Consortium.","year":"2012","unstructured":"Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 486, 207\u2013214 (2012).","journal-title":"Nature"},{"key":"785_CR60","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41591-020-0963-8","volume":"26","author":"DM Keohane","year":"2020","unstructured":"Keohane, D. M. et al. Microbiome and health implications for ethnic minorities after enforced lifestyle changes. Nat. Med. 26, 1089\u20131095 (2020).","journal-title":"Nat. Med."},{"key":"785_CR61","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1126\/science.aad3369","volume":"352","author":"A Zhernakova","year":"2016","unstructured":"Zhernakova, A. et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 352, 565\u2013569 (2016).","journal-title":"Science"},{"key":"785_CR62","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41586-020-2269-x","volume":"581","author":"S Vieira-Silva","year":"2020","unstructured":"Vieira-Silva, S. et al. Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. Nature 581, 310\u2013315 (2020).","journal-title":"Nature"},{"key":"785_CR63","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nbt.2939","volume":"32","author":"HB Nielsen","year":"2014","unstructured":"Nielsen, H. B. et al. Identification and assembly of genomes and genetic elements in complex metagenomic samples without using reference genomes. Nat. Biotechnol. 32, 822\u2013828 (2014).","journal-title":"Nat. Biotechnol."},{"key":"785_CR64","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature11450","volume":"490","author":"J Qin","year":"2012","unstructured":"Qin, J. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55\u201360 (2012).","journal-title":"Nature"},{"key":"785_CR65","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nature13568","volume":"513","author":"N Qin","year":"2014","unstructured":"Qin, N. et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 513, 59\u201364 (2014).","journal-title":"Nature"},{"key":"785_CR66","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1016\/j.cell.2016.11.046","volume":"167","author":"M Schirmer","year":"2016","unstructured":"Schirmer, M. et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell 167, 1897 (2016).","journal-title":"Cell"},{"key":"785_CR67","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.cels.2016.10.004","volume":"3","author":"H Xie","year":"2016","unstructured":"Xie, H. et al. Shotgun metagenomics of 250 adult twins reveals genetic and environmental impacts on the gut microbiome. Cell Syst. 3, 572\u2013584.e3 (2016).","journal-title":"Cell Syst."},{"key":"785_CR68","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.cell.2015.11.001","volume":"163","author":"D Zeevi","year":"2015","unstructured":"Zeevi, D. et al. Personalized nutrition by prediction of glycemic responses. Cell 163, 1079\u20131094 (2015).","journal-title":"Cell"},{"key":"785_CR69","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1126\/science.aay9189","volume":"368","author":"D Nejman","year":"2020","unstructured":"Nejman, D. et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science 368, 973\u2013980 (2020).","journal-title":"Science"},{"key":"785_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114277","volume":"9","author":"B Bogert","year":"2014","unstructured":"Bogert, B., van den, Meijerink, M., Zoetendal, E. G., Wells, J. M. & Kleerebezem, M. Immunomodulatory properties of Streptococcus and Veillonella isolates from the human small intestine microbiota. PLoS ONE 9, e114277 (2014).","journal-title":"PLoS ONE"},{"key":"785_CR71","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.3390\/cancers12082220","volume":"12","author":"H-E Hong","year":"2020","unstructured":"Hong, H.-E., Kim, A.-S., Kim, M.-R., Ko, H.-J. & Jung, M. K. Does the use of proton pump inhibitors increase the risk of pancreatic cancer? A systematic review and meta-analysis of epidemiologic studies. Cancers 12, 2220 (2020).","journal-title":"Cancers"},{"key":"785_CR72","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1158\/1940-6207.CAPR-14-0129","volume":"7","author":"JP Zackular","year":"2014","unstructured":"Zackular, J. P., Rogers, M. A. M., Ruffin, M. T. & Schloss, P. D. The human gut microbiome as a screening tool for colorectal cancer. Cancer Prev. Res. 7, 1112\u20131121 (2014).","journal-title":"Cancer Prev. Res."},{"key":"785_CR73","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.65088","volume":"10","author":"F Beghini","year":"2021","unstructured":"Beghini, F. et al. Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. Elife 10, e65088 (2021).","journal-title":"Elife"},{"key":"785_CR74","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.chom.2013.07.012","volume":"14","author":"MR Rubinstein","year":"2013","unstructured":"Rubinstein, M. R. et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin\/\u03b2-catenin signaling via its FadA adhesin. Cell Host Microbe 14, 195\u2013206 (2013).","journal-title":"Cell Host Microbe"},{"key":"785_CR75","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1038\/s41564-019-0541-3","volume":"4","author":"X Long","year":"2019","unstructured":"Long, X. et al. Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity. Nat. Microbiol. 4, 2319\u20132330 (2019).","journal-title":"Nat. Microbiol."},{"key":"785_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41522-017-0040-3","volume":"3","author":"JL Drewes","year":"2017","unstructured":"Drewes, J. L. et al. High-resolution bacterial 16S rRNA gene profile meta-analysis and biofilm status reveal common colorectal cancer consortia. NPJ Biofilms Microbiomes 3, 34 (2017).","journal-title":"NPJ Biofilms Microbiomes"},{"key":"785_CR77","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1136\/gutjnl-2017-314814","volume":"67","author":"B Flemer","year":"2018","unstructured":"Flemer, B. et al. The oral microbiota in colorectal cancer is distinctive and predictive. Gut 67, 1454\u20131463 (2018).","journal-title":"Gut"},{"key":"785_CR78","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.42693","volume":"8","author":"TS Schmidt","year":"2019","unstructured":"Schmidt, T. S. et al. Extensive transmission of microbes along the gastrointestinal tract. Elife 8, e42693 (2019).","journal-title":"Elife"},{"key":"785_CR79","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1053\/j.gastro.2018.04.018","volume":"155","author":"G Nakatsu","year":"2018","unstructured":"Nakatsu, G. et al. Alterations in enteric virome are associated with colorectal cancer and survival outcomes. Gastroenterology 155, 529\u2013541.e5 (2018).","journal-title":"Gastroenterology"},{"key":"785_CR80","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1172\/JCI124196","volume":"129","author":"S Tomkovich","year":"2019","unstructured":"Tomkovich, S. et al. Human colon mucosal biofilms from healthy or colon cancer hosts are carcinogenic. J. Clin. Invest. 129, 1699\u20131712 (2019).","journal-title":"J. Clin. Invest."},{"key":"785_CR81","doi-asserted-by":"publisher","first-page":"18321","DOI":"10.1073\/pnas.1406199111","volume":"111","author":"CM Dejea","year":"2014","unstructured":"Dejea, C. M. et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc. Natl Acad. Sci. USA 111, 18321\u201318326 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"785_CR82","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1158\/1055-9965.EPI-18-1111","volume":"28","author":"RN Lui","year":"2019","unstructured":"Lui, R. N. et al. Global increasing incidence of young-onset colorectal cancer across 5 continents: a joinpoint regression analysis of 1,922,167 cases. Cancer Epidemiol. Biomark. Prev. 28, 1275\u20131282 (2019).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"785_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27112-y","volume":"12","author":"Y Yang","year":"2021","unstructured":"Yang, Y. et al. Dysbiosis of human gut microbiome in young-onset colorectal cancer. Nat. Commun. 12, 6757 (2021).","journal-title":"Nat. Commun."},{"key":"785_CR84","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327156","author":"C Kong","year":"2022","unstructured":"Kong, C. et al. Integrated metagenomic and metabolomic analysis reveals distinct gut-microbiome-derived phenotypes in early-onset colorectal cancer. Gut https:\/\/doi.org\/10.1136\/gutjnl-2022-327156 (2022).","journal-title":"Gut"},{"key":"785_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-019-0667-z","volume":"17","author":"AM Thomas","year":"2019","unstructured":"Thomas, A. M. & Segata, N. Multiple levels of the unknown in microbiome research. BMC Biol. 17, 48 (2019).","journal-title":"BMC Biol."},{"key":"785_CR86","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1053\/j.gastro.2022.06.038","volume":"163","author":"Y Lin","year":"2022","unstructured":"Lin, Y. et al. Altered mycobiota signatures and enriched pathogenic Aspergillus rambellii are associated with colorectal cancer based on multicohort fecal metagenomic analyses. Gastroenterology 163, 908\u2013921 (2022).","journal-title":"Gastroenterology"},{"key":"785_CR87","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41564-021-01030-7","volume":"7","author":"N-N Liu","year":"2022","unstructured":"Liu, N.-N. et al. Multi-kingdom microbiota analyses identify bacterial-fungal interactions and biomarkers of colorectal cancer across cohorts. Nat. Microbiol. 7, 238\u2013250 (2022).","journal-title":"Nat. Microbiol."},{"key":"785_CR88","doi-asserted-by":"publisher","first-page":"eaax0182","DOI":"10.1126\/science.aax0182","volume":"367","author":"SL Topalian","year":"2020","unstructured":"Topalian, S. L., Taube, J. M. & Pardoll, D. M. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science 367, eaax0182 (2020).","journal-title":"Science"},{"key":"785_CR89","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1053\/j.gastro.2020.11.041","volume":"160","author":"V Matson","year":"2021","unstructured":"Matson, V., Chervin, C. S. & Gajewski, T. F. Cancer and the microbiome\u2013influence of the commensal microbiota on cancer, immune responses, and immunotherapy. Gastroenterology 160, 600\u2013613 (2021).","journal-title":"Gastroenterology"},{"key":"785_CR90","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1158\/2159-8290.CD-21-0236","volume":"11","author":"L Derosa","year":"2021","unstructured":"Derosa, L. et al. Microbiota-centered interventions: the next breakthrough in immuno-oncology? Cancer Discov. 11, 2396\u20132412 (2021).","journal-title":"Cancer Discov."},{"key":"785_CR91","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104\u2013108 (2018).","journal-title":"Science"},{"key":"785_CR92","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1158\/2326-6066.CIR-20-0196","volume":"8","author":"T Hakozaki","year":"2020","unstructured":"Hakozaki, T. et al. The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non-small cell lung cancer. Cancer Immunol. Res. 8, 1243\u20131250 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"785_CR93","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","volume":"27","author":"T Cascone","year":"2021","unstructured":"Cascone, T. et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat. Med. 27, 504\u2013514 (2021).","journal-title":"Nat. Med."},{"key":"785_CR94","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.eururo.2020.07.011","volume":"78","author":"NJ Salgia","year":"2020","unstructured":"Salgia, N. J. et al. Stool microbiome profiling of patients with metastatic renal cell carcinoma receiving anti-PD-1 immune checkpoint inhibitors. Eur. Urol. 78, 498\u2013502 (2020).","journal-title":"Eur. Urol."},{"key":"785_CR95","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.jtho.2019.04.007","volume":"14","author":"Y Jin","year":"2019","unstructured":"Jin, Y. et al. The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in chinese patients with NSCLC. J. Thorac. Oncol. 14, 1378\u20131389 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"785_CR96","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01037-7","volume":"14","author":"RC Newsome","year":"2022","unstructured":"Newsome, R. C. et al. Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort. Genome Med. 14, 35 (2022).","journal-title":"Genome Med."},{"key":"785_CR97","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/s41591-022-01779-2","volume":"28","author":"EM Park","year":"2022","unstructured":"Park, E. M. et al. Targeting the gut and tumor microbiota in cancer. Nat. Med. 28, 690\u2013703 (2022).","journal-title":"Nat. Med."},{"key":"785_CR98","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003334","volume":"9","author":"J Mao","year":"2021","unstructured":"Mao, J. et al. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. J. Immunother. Cancer 9, e003334 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"785_CR99","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1158\/2326-6066.CIR-19-1014","volume":"8","author":"Z Peng","year":"2020","unstructured":"Peng, Z. et al. The gut microbiome is associated with clinical response to anti-PD-1\/PD-L1 immunotherapy in gastrointestinal cancer. Cancer Immunol. Res. 8, 1251\u20131261 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"785_CR100","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s40425-019-0650-9","volume":"7","author":"Y Zheng","year":"2019","unstructured":"Zheng, Y. et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J. Immunother. Cancer 7, 193 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"785_CR101","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-019-0495-2","volume":"25","author":"C Depommier","year":"2019","unstructured":"Depommier, C. et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat. Med. 25, 1096\u20131103 (2019).","journal-title":"Nat. Med."},{"key":"785_CR102","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/gutjnl-2021-326789","volume":"71","author":"WM de Vos","year":"2022","unstructured":"de Vos, W. M., Tilg, H., Van Hul, M. & Cani, P. D. Gut microbiome and health: mechanistic insights. Gut 71, 1020\u20131032 (2022).","journal-title":"Gut"},{"key":"785_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31312-5","volume":"13","author":"KM Schneider","year":"2022","unstructured":"Schneider, K. M. et al. Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment. Nat. Commun. 13, 3964 (2022).","journal-title":"Nat. Commun."},{"key":"785_CR104","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1126\/science.aaw7479","volume":"364","author":"E Ansaldo","year":"2019","unstructured":"Ansaldo, E. et al. Akkermansia muciniphila induces intestinal adaptive immune responses during homeostasis. Science 364, 1179\u20131184 (2019).","journal-title":"Science"},{"key":"785_CR105","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41591-022-02189-0","volume":"29","author":"T Cascone","year":"2023","unstructured":"Cascone, T. et al. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat. Med. 29, 593\u2013604 (2023).","journal-title":"Nat. Med."},{"key":"785_CR106","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1007\/s00262-022-03169-6","volume":"71","author":"FY Shaikh","year":"2022","unstructured":"Shaikh, F. Y. et al. Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors. Cancer Immunol. Immunother. 71, 2405\u20132420 (2022).","journal-title":"Cancer Immunol. Immunother."},{"key":"785_CR107","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1158\/1078-0432.CCR-20-4834","volume":"27","author":"FY Shaikh","year":"2021","unstructured":"Shaikh, F. Y. et al. A uniform computational approach improved on existing pipelines to reveal microbiome biomarkers of nonresponse to immune checkpoint inhibitors. Clin. Cancer Res. 27, 2571\u20132583 (2021).","journal-title":"Clin. Cancer Res."},{"key":"785_CR108","doi-asserted-by":"publisher","first-page":"140940","DOI":"10.1172\/jci.insight.140940","volume":"5","author":"A Limeta","year":"2020","unstructured":"Limeta, A., Ji, B., Levin, M., Gatto, F. & Nielsen, J. Meta-analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma. JCI Insight 5, 140940 (2020).","journal-title":"JCI Insight"},{"key":"785_CR109","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1038\/s41591-018-0164-x","volume":"24","author":"Y He","year":"2018","unstructured":"He, Y. et al. Regional variation limits applications of healthy gut microbiome reference ranges and disease models. Nat. Med. 24, 1532\u20131535 (2018).","journal-title":"Nat. Med."},{"key":"785_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01965-2","author":"RC Simpson","year":"2022","unstructured":"Simpson, R. C. et al. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-022-01965-2 (2022).","journal-title":"Nat. Med."},{"key":"785_CR111","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1126\/science.1240527","volume":"342","author":"N Iida","year":"2013","unstructured":"Iida, N. et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342, 967\u2013970 (2013).","journal-title":"Science"},{"key":"785_CR112","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/j.gastro.2017.07.047","volume":"153","author":"AN Hegazy","year":"2017","unstructured":"Hegazy, A. N. et al. Circulating and tissue-resident CD4+ T cells with reactivity to intestinal microbiota are abundant in healthy individuals and function is altered during inflammation. Gastroenterology 153, 1320\u20131337.e16 (2017).","journal-title":"Gastroenterology"},{"key":"785_CR113","doi-asserted-by":"publisher","first-page":"842911","DOI":"10.3389\/fimmu.2022.842911","volume":"13","author":"AR Bourgonje","year":"2022","unstructured":"Bourgonje, A. R. et al. Patients with inflammatory bowel disease show IgG immune responses towards specific intestinal bacterial genera. Front. Immunol. 13, 842911 (2022).","journal-title":"Front. Immunol."},{"key":"785_CR114","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1172\/JCI200420295","volume":"113","author":"MJ Lodes","year":"2004","unstructured":"Lodes, M. J. et al. Bacterial flagellin is a dominant antigen in Crohn disease. J. Clin. Invest. 113, 1296\u20131306 (2004).","journal-title":"J. Clin. Invest."},{"key":"785_CR115","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41586-019-1237-9","volume":"569","author":"J Lloyd-Price","year":"2019","unstructured":"Lloyd-Price, J. et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature 569, 655\u2013662 (2019).","journal-title":"Nature"},{"key":"785_CR116","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/19490976.2019.1626683","volume":"11","author":"S Rengarajan","year":"2020","unstructured":"Rengarajan, S. et al. Dynamic immunoglobulin responses to gut bacteria during inflammatory bowel disease. Gut Microbes 11, 405\u2013420 (2020).","journal-title":"Gut Microbes"},{"key":"785_CR117","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1016\/j.immuni.2021.11.003","volume":"54","author":"AE Overacre-Delgoffe","year":"2021","unstructured":"Overacre-Delgoffe, A. E. et al. Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer. Immunity 54, 2812\u20132824.e4 (2021).","journal-title":"Immunity"},{"key":"785_CR118","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03135-8","author":"A Noble","year":"2022","unstructured":"Noble, A. et al. Altered immunity to microbiota, B cell activation and depleted \u03b3\u03b4\/resident memory T cells in colorectal cancer. Cancer Immunol. Immunother. https:\/\/doi.org\/10.1007\/s00262-021-03135-8 (2022).","journal-title":"Cancer Immunol. Immunother."},{"key":"785_CR119","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","volume":"55","author":"M Meylan","year":"2022","unstructured":"Meylan, M. et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 55, 527\u2013541.e5 (2022).","journal-title":"Immunity"},{"key":"785_CR120","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0201","author":"A-G Goubet","year":"2022","unstructured":"Goubet, A.-G. et al. Escherichia coli-specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0201 (2022).","journal-title":"Cancer Discov."},{"key":"785_CR121","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41590-020-0688-3","volume":"21","author":"J Wu","year":"2020","unstructured":"Wu, J. et al. A highly polarized TH2 bladder response to infection promotes epithelial repair at the expense of preventing new infections. Nat. Immunol. 21, 671\u2013683 (2020).","journal-title":"Nat. Immunol."},{"key":"785_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.12.010","author":"A Yacouba","year":"2022","unstructured":"Yacouba, A., Tidjani Alou, M., Lagier, J.-C., Dubourg, G. & Raoult, D. Urinary microbiota and bladder cancer: a systematic review and a focus on uropathogens. Semin. Cancer Biol. https:\/\/doi.org\/10.1016\/j.semcancer.2021.12.010 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"785_CR123","doi-asserted-by":"publisher","first-page":"102171","DOI":"10.1016\/j.coi.2022.102171","volume":"75","author":"L Zitvogel","year":"2022","unstructured":"Zitvogel, L. & Kroemer, G. Cross-reactivity between microbial and tumor antigens. Curr. Opin. Immunol. 75, 102171 (2022).","journal-title":"Curr. Opin. Immunol."},{"key":"785_CR124","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1126\/science.aax0701","volume":"369","author":"A Fluckiger","year":"2020","unstructured":"Fluckiger, A. et al. Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage. Science 369, 936\u2013942 (2020).","journal-title":"Science"},{"key":"785_CR125","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","volume":"350","author":"M V\u00e9tizou","year":"2015","unstructured":"V\u00e9tizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079\u20131084 (2015).","journal-title":"Science"},{"key":"785_CR126","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.immuni.2016.09.009","volume":"45","author":"R Daill\u00e8re","year":"2016","unstructured":"Daill\u00e8re, R. et al. Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity 45, 931\u2013943 (2016).","journal-title":"Immunity"},{"key":"785_CR127","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.yexcr.2017.07.009","volume":"358","author":"Y Rong","year":"2017","unstructured":"Rong, Y. et al. Reactivity toward Bifidobacterium longum and Enterococcus hirae demonstrate robust CD8+ T cell response and better prognosis in HBV-related hepatocellular carcinoma. Exp. Cell Res. 358, 352\u2013359 (2017).","journal-title":"Exp. Cell Res."},{"key":"785_CR128","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","volume":"371","author":"D Davar","year":"2021","unstructured":"Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371, 595\u2013602 (2021).","journal-title":"Science"},{"key":"785_CR129","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41591-022-01702-9","volume":"28","author":"M Smith","year":"2022","unstructured":"Smith, M. et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat. Med. 28, 713\u2013723 (2022).","journal-title":"Nat. Med."},{"key":"785_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13999-5","volume":"7","author":"CM Whitfield-Cargile","year":"2017","unstructured":"Whitfield-Cargile, C. M. et al. The non-invasive exfoliated transcriptome (exfoliome) reflects the tissue-level transcriptome in a mouse model of NSAID enteropathy. Sci. Rep. 7, 14687 (2017).","journal-title":"Sci. Rep."},{"key":"785_CR131","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.cell.2016.05.041","volume":"165","author":"A Koh","year":"2016","unstructured":"Koh, A., De Vadder, F., Kovatcheva-Datchary, P. & B\u00e4ckhed, F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell 165, 1332\u20131345 (2016).","journal-title":"Cell"},{"key":"785_CR132","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3945\/jn.112.169672","volume":"143","author":"D Haenen","year":"2013","unstructured":"Haenen, D. et al. A diet high in resistant starch modulates microbiota composition, SCFA concentrations, and gene expression in pig intestine. J. Nutr. 143, 274\u2013283 (2013).","journal-title":"J. Nutr."},{"key":"785_CR133","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nature12726","volume":"504","author":"N Arpaia","year":"2013","unstructured":"Arpaia, N. et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504, 451\u2013455 (2013).","journal-title":"Nature"},{"key":"785_CR134","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1126\/science.1241165","volume":"341","author":"PM Smith","year":"2013","unstructured":"Smith, P. M. et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341, 569\u2013573 (2013).","journal-title":"Science"},{"key":"785_CR135","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.4049\/jimmunol.1502046","volume":"196","author":"J Park","year":"2016","unstructured":"Park, J., Goergen, C. J., HogenEsch, H. & Kim, C. H. Chronically elevated levels of short-chain fatty acids induce T cell-mediated ureteritis and hydronephrosis. J. Immunol. 196, 2388\u20132400 (2016).","journal-title":"J. Immunol."},{"key":"785_CR136","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.3389\/fimmu.2017.01036","volume":"8","author":"M Kespohl","year":"2017","unstructured":"Kespohl, M. et al. The microbial metabolite butyrate induces expression of Th1-associated factors in CD4+ T cells. Front. Immunol. 8, 1036 (2017).","journal-title":"Front. Immunol."},{"key":"785_CR137","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/ni.3713","volume":"18","author":"E Mari\u00f1o","year":"2017","unstructured":"Mari\u00f1o, E. et al. Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes. Nat. Immunol. 18, 552\u2013562 (2017).","journal-title":"Nat. Immunol."},{"key":"785_CR138","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/ni.3400","volume":"17","author":"ND Mathewson","year":"2016","unstructured":"Mathewson, N. D. et al. Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat. Immunol. 17, 505\u2013513 (2016).","journal-title":"Nat. Immunol."},{"key":"785_CR139","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.immuni.2018.04.022","volume":"48","author":"A Trompette","year":"2018","unstructured":"Trompette, A. et al. Dietary fiber confers protection against flu by shaping Ly6c\u2212 patrolling monocyte hematopoiesis and CD8+ T cell metabolism. Immunity 48, 992\u20131005.e8 (2018).","journal-title":"Immunity"},{"key":"785_CR140","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.immuni.2019.06.002","volume":"51","author":"A Bachem","year":"2019","unstructured":"Bachem, A. et al. Microbiota-derived short-chain fatty acids promote the memory potential of antigen-activated CD8+ T cells. Immunity 51, 285\u2013297.e5 (2019).","journal-title":"Immunity"},{"key":"785_CR141","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08711-2","volume":"10","author":"M Luu","year":"2019","unstructured":"Luu, M. et al. The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes. Nat. Commun. 10, 760 (2019).","journal-title":"Nat. Commun."},{"key":"785_CR142","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201073","volume":"13","author":"S Yuille","year":"2018","unstructured":"Yuille, S., Reichardt, N., Panda, S., Dunbar, H. & Mulder, I. E. Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid. PLoS ONE 13, e0201073 (2018).","journal-title":"PLoS ONE"},{"key":"785_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24331-1","volume":"12","author":"M Luu","year":"2021","unstructured":"Luu, M. et al. Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer. Nat. Commun. 12, 4077 (2021).","journal-title":"Nat. Commun."},{"key":"785_CR144","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.2895","volume":"3","author":"M Nomura","year":"2020","unstructured":"Nomura, M. et al. Association of short-chain fatty acids in the gut microbiome with clinical response to treatment with nivolumab or pembrolizumab in patients with solid cancer tumors. JAMA Netw. Open 3, e202895 (2020).","journal-title":"JAMA Netw. Open"},{"key":"785_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16079-x","volume":"11","author":"C Coutzac","year":"2020","unstructured":"Coutzac, C. et al. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. Nat. Commun. 11, 2168 (2020).","journal-title":"Nat. Commun."},{"key":"785_CR146","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1172\/JCI124332","volume":"130","author":"M Uribe-Herranz","year":"2020","unstructured":"Uribe-Herranz, M. et al. Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response. J. Clin. Invest. 130, 466\u2013479 (2020).","journal-title":"J. Clin. Invest."},{"key":"785_CR147","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1084\/jem.189.9.1363","volume":"189","author":"DH Munn","year":"1999","unstructured":"Munn, D. H. et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189, 1363\u20131372 (1999).","journal-title":"J. Exp. Med."},{"key":"785_CR148","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nm934","volume":"9","author":"C Uyttenhove","year":"2003","unstructured":"Uyttenhove, C. et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9, 1269\u20131274 (2003).","journal-title":"Nat. Med."},{"key":"785_CR149","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.2147\/OTT.S136259","volume":"10","author":"Y Wang","year":"2017","unstructured":"Wang, Y., Hu, G.-F. & Wang, Z.-H. The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy. Onco Targets Ther. 10, 3557\u20133566 (2017).","journal-title":"Onco Targets Ther."},{"key":"785_CR150","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1084\/jem.20130066","volume":"210","author":"RB Holmgaard","year":"2013","unstructured":"Holmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D. & Allison, J. P. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J. Exp. Med. 210, 1389\u20131402 (2013).","journal-title":"J. Exp. Med."},{"key":"785_CR151","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1595-3","volume":"16","author":"A Botticelli","year":"2018","unstructured":"Botticelli, A. et al. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC? J. Transl. Med. 16, 219 (2018).","journal-title":"J. Transl. Med."},{"key":"785_CR152","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12361-9","volume":"10","author":"H Li","year":"2019","unstructured":"Li, H. et al. Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nat. Commun. 10, 4346 (2019).","journal-title":"Nat. Commun."},{"key":"785_CR153","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","volume":"20","author":"GV Long","year":"2019","unstructured":"Long, G. V. et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 20, 1083\u20131097 (2019).","journal-title":"Lancet Oncol."},{"key":"785_CR154","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3389\/fnins.2019.01365","volume":"13","author":"H Kaur","year":"2019","unstructured":"Kaur, H., Bose, C. & Mande, S. S. Tryptophan metabolism by gut microbiome and gut-brain-axis: an in silico analysis. Front. Neurosci. 13, 1365 (2019).","journal-title":"Front. Neurosci."},{"key":"785_CR155","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.cell.2023.03.011","volume":"186","author":"MJ Bender","year":"2023","unstructured":"Bender, M. J. et al. Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell 186, 1846\u20131862.e26 (2023).","journal-title":"Cell"},{"key":"785_CR156","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41591-018-0060-4","volume":"24","author":"L Laurans","year":"2018","unstructured":"Laurans, L. et al. Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health. Nat. Med. 24, 1113\u20131120 (2018).","journal-title":"Nat. Med."},{"key":"785_CR157","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1038\/s41418-021-00817-9","volume":"28","author":"A-G Goubet","year":"2021","unstructured":"Goubet, A.-G. et al. Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. Cell Death Differ. 28, 3297\u20133315 (2021).","journal-title":"Cell Death Differ."},{"key":"785_CR158","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03540-y","volume":"12","author":"F-X Danlos","year":"2021","unstructured":"Danlos, F.-X. et al. Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. Cell Death Dis. 12, 258 (2021).","journal-title":"Cell Death Dis."},{"key":"785_CR159","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.annonc.2022.07.001","volume":"33","author":"F Peyraud","year":"2022","unstructured":"Peyraud, F. et al. Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors. Ann. Oncol. 33, 1041\u20131051 (2022).","journal-title":"Ann. Oncol."},{"key":"785_CR160","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2016.09.031","volume":"167","author":"R Geiger","year":"2016","unstructured":"Geiger, R. et al. L-Arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell 167, 829\u2013842.e13 (2016).","journal-title":"Cell"},{"key":"785_CR161","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41586-021-04003-2","volume":"598","author":"FP Canale","year":"2021","unstructured":"Canale, F. P. et al. Metabolic modulation of tumours with engineered bacteria for immunotherapy. Nature 598, 662\u2013666 (2021).","journal-title":"Nature"},{"key":"785_CR162","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1158\/2159-8290.CD-21-0808","volume":"12","author":"M Messaoudene","year":"2022","unstructured":"Messaoudene, M. et al. A natural polyphenol exerts antitumor activity and circumvents anti-PD-1 resistance through effects on the gut microbiota. Cancer Discov. 12, 1070\u20131087 (2022).","journal-title":"Cancer Discov."},{"key":"785_CR163","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.18632\/aging.202739","volume":"13","author":"C Grajeda-Iglesias","year":"2021","unstructured":"Grajeda-Iglesias, C. et al. Oral administration of Akkermansia muciniphila elevates systemic antiaging and anticancer metabolites. Aging 13, 6375\u20136405 (2021).","journal-title":"Aging"},{"key":"785_CR164","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0504","author":"L Mont\u00e9gut","year":"2022","unstructured":"Mont\u00e9gut, L., de Cabo, R., Zitvogel, L. & Kroemer, G. Science-driven nutritional interventions for the prevention and treatment of cancer. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0504 (2022).","journal-title":"Cancer Discov."},{"key":"785_CR165","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ccell.2016.05.016","volume":"30","author":"F Pietrocola","year":"2016","unstructured":"Pietrocola, F. et al. Caloric restriction mimetics enhance anticancer immunosurveillance. Cancer Cell 30, 147\u2013160 (2016).","journal-title":"Cancer Cell"},{"key":"785_CR166","doi-asserted-by":"publisher","first-page":"20860","DOI":"10.18632\/aging.203525","volume":"13","author":"M Bourgin","year":"2021","unstructured":"Bourgin, M. et al. Circulating acetylated polyamines correlate with Covid-19 severity in cancer patients. Aging 13, 20860\u201320885 (2021).","journal-title":"Aging"},{"key":"785_CR167","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1126\/science.abc3421","volume":"369","author":"LF Mager","year":"2020","unstructured":"Mager, L. F. et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science 369, 1481\u20131489 (2020).","journal-title":"Science"},{"key":"785_CR168","doi-asserted-by":"publisher","first-page":"678753","DOI":"10.3389\/fmolb.2021.678753","volume":"8","author":"X Nie","year":"2021","unstructured":"Nie, X. et al. Serum metabolite biomarkers predictive of response to PD-1 blockade therapy in non-small cell lung cancer. Front. Mol. Biosci. 8, 678753 (2021).","journal-title":"Front. Mol. Biosci."},{"key":"785_CR169","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1182\/blood.2019003990","volume":"136","author":"K Wu","year":"2020","unstructured":"Wu, K. et al. The gut microbial metabolite trimethylamine N-oxide aggravates GVHD by inducing M1 macrophage polarization in mice. Blood 136, 501\u2013515 (2020).","journal-title":"Blood"},{"key":"785_CR170","doi-asserted-by":"publisher","first-page":"eabn0704","DOI":"10.1126\/sciimmunol.abn0704","volume":"7","author":"G Mirji","year":"2022","unstructured":"Mirji, G. et al. The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer. Sci. Immunol. 7, eabn0704 (2022).","journal-title":"Sci. Immunol."},{"key":"785_CR171","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1016\/j.cell.2022.09.005","volume":"185","author":"L Narunsky-Haziza","year":"2022","unstructured":"Narunsky-Haziza, L. et al. Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions. Cell 185, 3789\u20133806.e17 (2022).","journal-title":"Cell"},{"key":"785_CR172","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2095-1","volume":"579","author":"GD Poore","year":"2020","unstructured":"Poore, G. D. et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature 579, 567\u2013574 (2020).","journal-title":"Nature"},{"key":"785_CR173","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/s41591-023-02234-6","volume":"29","author":"CK Stein-Thoeringer","year":"2023","unstructured":"Stein-Thoeringer, C. K. et al. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat. Med. 29, 906\u2013916 (2023).","journal-title":"Nat. Med."},{"issue":"Suppl. 15","key":"785_CR174","doi-asserted-by":"publisher","first-page":"TPS8105","DOI":"10.1200\/jco.2015.33.15_suppl.tps8105","volume":"33","author":"T Mok","year":"2015","unstructured":"Mok, T. et al. Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1\u2013positive advanced non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 33 (Suppl. 15), TPS8105 (2015).","journal-title":"J. Clin. Oncol."},{"key":"785_CR175","unstructured":"Center for Devices and Radiological Health. List of cleared or approved companion diagnostic devices (in vitro and imaging tools) (FDA, 2023)."},{"key":"785_CR176","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J. Clin. Oncol. 38, 1\u201310 (2020).","journal-title":"J. Clin. Oncol."},{"key":"785_CR177","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189\u20132199 (2014).","journal-title":"N. Engl. J. Med."},{"key":"785_CR178","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","volume":"36","author":"H Rizvi","year":"2018","unstructured":"Rizvi, H. et al. Molecular determinants of response to anti-programmed cell death (PD)\u22121 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J. Clin. Oncol. 36, 633\u2013641 (2018).","journal-title":"J. Clin. Oncol."},{"key":"785_CR179","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1056\/NEJMc2031965","volume":"384","author":"B Rousseau","year":"2021","unstructured":"Rousseau, B. et al. The spectrum of benefit from checkpoint blockade in hypermutated tumors. N. Engl. J. Med. 384, 1168\u20131170 (2021).","journal-title":"N. Engl. J. Med."},{"key":"785_CR180","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann, M. D. et al. Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093\u20132104 (2018).","journal-title":"N. Engl. J. Med."},{"key":"785_CR181","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","volume":"4","author":"L Mezquita","year":"2018","unstructured":"Mezquita, L. et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol. 4, 351\u2013357 (2018).","journal-title":"JAMA Oncol."},{"key":"785_CR182","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34398-4","volume":"8","author":"H-Y Yoon","year":"2018","unstructured":"Yoon, H.-Y. et al. Association between neutrophil-to-lymphocyte ratio and gut microbiota in a large population: a retrospective cross-sectional study. Sci. Rep. 8, 16031 (2018).","journal-title":"Sci. Rep."},{"key":"785_CR183","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","volume":"26","author":"KA Schalper","year":"2020","unstructured":"Schalper, K. A. et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat. Med. 26, 688\u2013692 (2020).","journal-title":"Nat. Med."},{"key":"785_CR184","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41591-020-0860-1","volume":"26","author":"KC Yuen","year":"2020","unstructured":"Yuen, K. C. et al. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nat. Med. 26, 693\u2013698 (2020).","journal-title":"Nat. Med."},{"key":"785_CR185","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41586-023-05728-y","volume":"615","author":"J Tintelnot","year":"2023","unstructured":"Tintelnot, J. et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature 615, 168\u2013174 (2023).","journal-title":"Nature"},{"key":"785_CR186","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.immuni.2022.01.006","volume":"55","author":"K Hezaveh","year":"2022","unstructured":"Hezaveh, K. et al. Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity. Immunity 55, 324\u2013340.e8 (2022).","journal-title":"Immunity"},{"key":"785_CR187","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/nprot.2016.091","volume":"11","author":"K Moor","year":"2016","unstructured":"Moor, K. et al. Analysis of bacterial-surface-specific antibodies in body fluids using bacterial flow cytometry. Nat. Protoc. 11, 1531\u20131553 (2016).","journal-title":"Nat. Protoc."},{"key":"785_CR188","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41586-021-03368-8","volume":"592","author":"S Kalaora","year":"2021","unstructured":"Kalaora, S. et al. Identification of bacteria-derived HLA-bound peptides in melanoma. Nature 592, 138\u2013143 (2021).","journal-title":"Nature"},{"key":"785_CR189","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30861-z","volume":"13","author":"E Mizukoshi","year":"2022","unstructured":"Mizukoshi, E. et al. Peptide vaccine-treated, long-term surviving cancer patients harbor self-renewing tumor-specific CD8+ T cells. Nat. Commun. 13, 3123 (2022).","journal-title":"Nat. Commun."},{"key":"785_CR190","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.fmre.2021.11.032","volume":"2","author":"J Liang","year":"2022","unstructured":"Liang, J. et al. Personalized cancer vaccines from bacteria-derived outer membrane vesicles with antibody-mediated persistent uptake by dendritic cells. Fundam. Res. 2, 23\u201336 (2022).","journal-title":"Fundam. Res."},{"key":"785_CR191","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22308-8","volume":"12","author":"K Cheng","year":"2021","unstructured":"Cheng, K. et al. Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via plug-and-display technology. Nat. Commun. 12, 2041 (2021).","journal-title":"Nat. Commun."},{"key":"785_CR192","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41522-022-00282-3","volume":"8","author":"C Li","year":"2022","unstructured":"Li, C. et al. Deep insights into the gut microbial community of extreme longevity in south Chinese centenarians by ultra-deep metagenomics and large-scale culturomics. NPJ Biofilms Microbiomes 8, 28 (2022).","journal-title":"NPJ Biofilms Microbiomes"},{"key":"785_CR193","doi-asserted-by":"publisher","DOI":"10.1128\/mSystems.00124-20","volume":"5","author":"S Rampelli","year":"2020","unstructured":"Rampelli, S. et al. Shotgun metagenomics of gut microbiota in humans with up to extreme longevity and the increasing role of xenobiotic degradation. mSystems 5, e00124-20 (2020).","journal-title":"mSystems"},{"key":"785_CR194","doi-asserted-by":"publisher","first-page":"2107288","DOI":"10.1080\/19490976.2022.2107288","volume":"14","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. The landscape in the gut microbiome of long-lived families reveals new insights on longevity and aging \u2013 relevant neural and immune function. Gut Microbes 14, 2107288 (2022).","journal-title":"Gut Microbes"},{"key":"785_CR195","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.3389\/fmicb.2020.01474","volume":"11","author":"Z Luan","year":"2020","unstructured":"Luan, Z. et al. Metagenomics study reveals changes in gut microbiota in centenarians: a cohort study of Hainan centenarians. Front. Microbiol. 11, 1474 (2020).","journal-title":"Front. Microbiol."},{"key":"785_CR196","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s43587-020-00014-2","volume":"1","author":"X Zhang","year":"2021","unstructured":"Zhang, X. et al. Sex- and age-related trajectories of the adult human gut microbiota shared across populations of different ethnicities. Nat. Aging 1, 87\u2013100 (2021).","journal-title":"Nat. Aging"},{"key":"785_CR197","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/nm.4358","volume":"23","author":"R Liu","year":"2017","unstructured":"Liu, R. et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat. Med. 23, 859\u2013868 (2017).","journal-title":"Nat. Med."},{"key":"785_CR198","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12866-018-1257-x","volume":"18","author":"Q Wang","year":"2018","unstructured":"Wang, Q. et al. A metagenome-wide association study of gut microbiota in asthma in UK adults. BMC Microbiol. 18, 114 (2018).","journal-title":"BMC Microbiol."},{"key":"785_CR199","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-18756-2","volume":"8","author":"X Cui","year":"2018","unstructured":"Cui, X. et al. Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients. Sci. Rep. 8, 635 (2018).","journal-title":"Sci. Rep."},{"key":"785_CR200","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41430-020-0607-6","volume":"74","author":"L Crovesy","year":"2020","unstructured":"Crovesy, L., Masterson, D. & Rosado, E. L. Profile of the gut microbiota of adults with obesity: a systematic review. Eur. J. Clin. Nutr. 74, 1251\u20131262 (2020).","journal-title":"Eur. J. Clin. Nutr."},{"key":"785_CR201","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19701-0","volume":"11","author":"KL Bowerman","year":"2020","unstructured":"Bowerman, K. L. et al. Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease. Nat. Commun. 11, 5886 (2020).","journal-title":"Nat. Commun."},{"key":"785_CR202","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-63475-w","volume":"10","author":"L Calder\u00f3n-P\u00e9rez","year":"2020","unstructured":"Calder\u00f3n-P\u00e9rez, L. et al. Gut metagenomic and short chain fatty acids signature in hypertension: a cross-sectional study. Sci. Rep. 10, 6436 (2020).","journal-title":"Sci. Rep."},{"key":"785_CR203","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1038\/s41396-021-00998-8","volume":"15","author":"Y Ni","year":"2021","unstructured":"Ni, Y. et al. Distinct composition and metabolic functions of human gut microbiota are associated with cachexia in lung cancer patients. ISME J. 15, 3207\u20133220 (2021).","journal-title":"ISME J."},{"key":"785_CR204","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1152\/physiolgenomics.00011.2021","volume":"53","author":"N Jiao","year":"2021","unstructured":"Jiao, N. et al. Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLD. Physiol. Genom. 53, 336\u2013348 (2021).","journal-title":"Physiol. Genom."},{"key":"785_CR205","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20422-7","volume":"12","author":"J Behary","year":"2021","unstructured":"Behary, J. et al. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. Nat. Commun. 12, 187 (2021).","journal-title":"Nat. Commun."},{"key":"785_CR206","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1053\/j.gastro.2020.08.054","volume":"160","author":"C Sol\u00e9","year":"2021","unstructured":"Sol\u00e9, C. et al. Alterations in gut microbiome in cirrhosis as assessed by quantitative metagenomics: relationship with acute-on-chronic liver failure and prognosis. Gastroenterology 160, 206\u2013218.e13 (2021).","journal-title":"Gastroenterology"},{"key":"785_CR207","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1161\/HYPERTENSIONAHA.121.17288","volume":"78","author":"M Nakai","year":"2021","unstructured":"Nakai, M. et al. Essential hypertension is associated with changes in gut microbial metabolic pathways: a multisite analysis of ambulatory blood pressure. Hypertension 78, 804\u2013815 (2021).","journal-title":"Hypertension"},{"key":"785_CR208","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28464-9","volume":"13","author":"O Aasmets","year":"2022","unstructured":"Aasmets, O., Krigul, K. L., L\u00fcll, K., Metspalu, A. & Org, E. Gut metagenome associations with extensive digital health data in a volunteer-based Estonian microbiome cohort. Nat. Commun. 13, 869 (2022).","journal-title":"Nat. Commun."},{"key":"785_CR209","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/apt.13568","volume":"43","author":"AG Clooney","year":"2016","unstructured":"Clooney, A. G. et al. A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Aliment. Pharmacol. Ther. 43, 974\u2013984 (2016).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"785_CR210","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","volume":"65","author":"F Imhann","year":"2016","unstructured":"Imhann, F. et al. Proton pump inhibitors affect the gut microbiome. Gut 65, 740\u2013748 (2016).","journal-title":"Gut"},{"key":"785_CR211","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3390\/microorganisms9020286","volume":"9","author":"Y-T Lin","year":"2021","unstructured":"Lin, Y.-T. et al. Anti-acid drug treatment induces changes in the gut microbiome composition of hemodialysis patients. Microorganisms 9, 286 (2021).","journal-title":"Microorganisms"},{"key":"785_CR212","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/s41564-018-0257-9","volume":"3","author":"A Palleja","year":"2018","unstructured":"Palleja, A. et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat. Microbiol. 3, 1255\u20131265 (2018).","journal-title":"Nat. Microbiol."},{"key":"785_CR213","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06862-0","volume":"7","author":"EPK Parker","year":"2017","unstructured":"Parker, E. P. K. et al. Changes in the intestinal microbiota following the administration of azithromycin in a randomised placebo-controlled trial among infants in south India. Sci. Rep. 7, 9168 (2017).","journal-title":"Sci. Rep."},{"key":"785_CR214","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.clnesp.2021.11.005","volume":"47","author":"G Singh","year":"2022","unstructured":"Singh, G. et al. The effect of gastric acid suppression on probiotic colonization in a double blinded randomized clinical trial. Clin. Nutr. ESPEN 47, 70\u201377 (2022).","journal-title":"Clin. Nutr. ESPEN"},{"key":"785_CR215","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14177-z","volume":"11","author":"A Vich Vila","year":"2020","unstructured":"Vich Vila, A. et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat. Commun. 11, 362 (2020).","journal-title":"Nat. Commun."},{"key":"785_CR216","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41391-021-00360-1","volume":"24","author":"JKM Li","year":"2021","unstructured":"Li, J. K. M. et al. A cross-sectional study on gut microbiota in prostate cancer patients with prostatectomy or androgen deprivation therapy. Prostate Cancer Prostatic Dis. 24, 1063\u20131072 (2021).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"785_CR217","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-09156-x","volume":"22","author":"NA Thompson","year":"2022","unstructured":"Thompson, N. A. et al. The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy. BMC Cancer 22, 99 (2022).","journal-title":"BMC Cancer"},{"key":"785_CR218","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1111\/1759-7714.14640","volume":"13","author":"F Shoji","year":"2022","unstructured":"Shoji, F. et al. Chronological analysis of the gut microbiome for efficacy of atezolizumab-based immunotherapy in non-small cell lung cancer: protocol for a multicenter prospective observational study. Thorac. Cancer 13, 2829\u20132833 (2022).","journal-title":"Thorac. Cancer"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-023-00785-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-023-00785-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-023-00785-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T10:07:07Z","timestamp":1692353227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-023-00785-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":218,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["785"],"URL":"https:\/\/doi.org\/10.1038\/s41571-023-00785-8","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,26]]},"assertion":[{"value":"10 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.M.T. is a new employee of Microbiotica. B.R. has received grants from AstraZeneca, Bristol Myers Squibb, Davoltera, Kaleido, Merck and Vedanta outside the submitted work; and has a patent pending (G17004\u201300006-AD, use of castalagin or analogues thereof for anticancer efficacy and to increase the response to immune-checkpoint inhibitors). G.K. has held research contracts with Daiichi Sankyo, Elior, Kaleido, Lytix Pharma, PharmaMar, Samsara, Sanofi, Tollys, Vascage and Vasculox\/Tioma; is on the Board of Directors of the Bristol Myers Squibb Foundation in France; is a scientific co-founder of EverImmune, Osasona Therapeutics, Samsara Therapeutics and Therafast Bio; and is an inventor in patents covering therapeutic targeting of ageing, cancer, cystic fibrosis and metabolic disorders. J.A.W. is an inventor on a US patent application (PCT\/US17\/53.717) submitted by the University of Texas MD Anderson Cancer Center, which covers methods to enhance immune-checkpoint inhibitor responses by modulating the microbiome; reports compensation for speaker\u2019s bureau and honoraria from Bristol Myers Squibb, Dava Oncology, Exelixis, Gilead, Illumina, Imedex, MedImmune, Omniprex, PeerView and Physician Education Resource; has served as a consultant or advisory board member for AstraZeneca, Bristol Myers Squibb, EverImmune, GlaxoSmithKline, Merck Novartis, Roche\/Genentech, Micronoma and OSE therapeutics; and receives stock options from Micronoma and OSE therapeutics. L.Z. is the scientific cofounder and President of the scientific advisory board of EverImmune, a company devoted to the use of commensal microorganisms (Oncobax) for the treatment of cancers; has received research grants from 9 meters, Daichi Sankyo, EverImmune and Pileje; is a former member of the board of directors of Transgene; and is a former consulting expert for Bristol Myers Squibb, GlaxoSmithKline, Lytix biotherapeutics and Tusk. M.F. and N.S. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}